Refractory Mixed Phenotype Acute Leukemia: Clinical Trials

10 trials for Refractory Mixed Phenotype Acute Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 recruiting, 3 active not recruiting, 1 terminated, 1 withdrawn. 8 Phase 1, 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 18Recruiting 5, Active not recruiting 2, Withdrawn 1
Phase 27Recruiting 4, Active not recruiting 1, Terminated 1, Withdrawn 1

Follow Refractory Mixed Phenotype Acute Leukemia: new trials by email Literature Review of Refractory Mixed Phenotype Acute Leukemia trials Research Report on Refractory Mixed Phenotype Acute Leukemia

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia
Phase 1 / Phase 2RecruitingFred Hutchinson Cancer Center362025-09-232026-05-15
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
Biospecimen Collection, Bone Marrow Aspiration, Calaspargase Pegol - Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia
Phase 2Active not recruitingChildren's Oncology Group782024-01-082026-08-25
Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane
Cytarabine, Fludarabine, Leucovorin - Acute Myeloid Leukemia Post Cytotoxic Therapy, Myelodysplastic Syndrome Post Cytotoxic Therapy
Phase 1Active not recruitingNational Cancer Institute (NCI)82023-10-102026-06-02
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat
Anti-CD123 ADC IMGN632, Bone Marrow Aspiration and Biopsy, Cytarabine - Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia
Phase 1 / Phase 2WithdrawnChildren's Oncology Group2023-08-012023-09-01
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Cladribine, Cytarabine, Mitoxantrone - Acute Biphenotypic Leukemia, Acute Myeloid Leukemia
Phase 1 / Phase 2RecruitingUniversity of Washington622022-02-042026-04-17
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Cladribine, Cyclophosphamide, Cyclosporine - Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia
Phase 1RecruitingFred Hutchinson Cancer Center1202020-12-032026-09-17
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Cyclophosphamide, Total-Body Irradiation - Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Phase 1 / Phase 2RecruitingFred Hutchinson Cancer Center302019-07-102026-06-22
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
Decitabine, Laboratory Biomarker Analysis, Venetoclax - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Phase 2TerminatedM.D. Anderson Cancer Center2352018-01-182026-03-10
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy - Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia
Phase 1Active not recruitingNational Cancer Institute (NCI)282017-10-252026-08-20
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Phase 1 / Phase 2RecruitingFred Hutchinson Cancer Center752017-10-242026-06-22

Narrower conditions

Leukemia, Biphenotypic, Acute (10)  ·  Leukemia, Myeloid, Acute (8)  ·  Leukemia, Myelomonocytic, Chronic (5)  ·  Myelodysplastic Syndromes (4)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (3)  ·  Anemia, Refractory, with Excess of Blasts (2)  ·  Burkitt Lymphoma (2)  ·  Blastic Plasmacytoid Dendritic Cell Neoplasm (1)  ·  Hematologic Neoplasms (1)  ·  Leukemia, Lymphoid (1)  ·  Leukemia, Monocytic, Acute (1)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Sarcoma, Myeloid (1)

Broader conditions

Hematologic Diseases (10)  ·  Hemic and Lymphatic Diseases (10)  ·  Immune System Diseases (10)  ·  Immunoproliferative Disorders (10)  ·  Leukemia (10)  ·  Lymphatic Diseases (10)  ·  Lymphoproliferative Disorders (10)  ·  Neoplasms (10)  ·  Neoplasms by Histologic Type (10)  ·  Leukemia, Lymphoid (9)  ·  Leukemia, Myeloid (8)  ·  Bone Marrow Diseases (6)  ·  Chronic Disease (5)  ·  Disease Attributes (5)  ·  Myelodysplastic-Myeloproliferative Diseases (5)

Interventions

Cytarabine (6)  ·  Biopsy (4)  ·  Whole-Body Irradiation (4)  ·  fludarabine phosphate (4)  ·  Injections (3)  ·  Mycophenolic Acid (3)  ·  Specimen Handling (3)  ·  X-Rays (3)  ·  fludarabine (3)  ·  Cladribine (2)  ·  Cyclophosphamide (2)  ·  Cyclosporine (2)  ·  Cyclosporins (2)  ·  Decitabine (2)  ·  Filgrastim (2)

Sponsors

Fred Hutchinson Cancer Center (4)  ·  Children's Oncology Group (2)  ·  National Cancer Institute (NCI) (2)  ·  M.D. Anderson Cancer Center (1)  ·  University of Washington (1)

Countries

United States (9)  ·  Canada (1)

Top investigators

Abhishek Maiti, MBBS (1)  ·  Brenda M. Sandmaier (1)  ·  Filippo Milano (1)  ·  Ivana Gojo (1)  ·  Kelly E Faulk (1)  ·  Maria Luisa Sulis (1)  ·  Mary-Beth M. Percival (1)  ·  Matthew A Kutny (1)  ·  Naveed Ali, MD (1)  ·  Phuong Vo (1)

Results publications

PMID 30335787, PMID 32896301, PMID 33027528, PMID 33580980, PMID 33792630, PMID 34255353, PMID 34474640, PMID 35622074, PMID 40535475

NIH funding

P01CA078902 (2), P30CA015704 (2), U10CA180886 (2), UM1CA186691 (1), UM1CA228823 (1)